- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2026 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.
Beyond the Excipient: Drug Formulation from Discovery Through Commercialization
Paul Smaltz, Senior Vice President of BASF Pharma Solutions, explains how the company acts as a strategic partner to the pharmaceutical industry by integrating AI-driven formulation tools, sustainability initiatives, and specialized biopharmaceutical solutions to overcome modern manufacturing challenges.
As the pharmaceutical landscape shifts toward asset-light models and increased outsourcing, BASF is evolving beyond its role as a traditional excipient manufacturer to provide deep technical expertise and R&D support. Through the implementation of generative AI and the ZoomLab® predictive modeling tool, BASF is helping customers accelerate formulation timelines and solve complex bioavailability issues with unprecedented precision. Smaltz also discusses the BASF commitment to "green transformation," pointing to the company’s goal of reaching net-zero emissions by 2050 while delivering high-performance and sustainable solutions for the growing biopharmaceutical market.